BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020

Dec 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-12-04

Reporting Person: Barnes Alane P (Senior VP, Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-04	Common Stock	M	13741	$4.15	Acquired	121802	Direct
2020-12-04	Common Stock	S	13741	$6.23	Disposed	108061	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-04	Emp. Stock Option (Right to Buy)	$4.15	M	13741	Disposed	2021-03-01	Common Stock (13741)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.22 to $6.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.